Skip to Content

Kintara Therapeutics Inc KTRA

Morningstar Rating
$0.12 0.00 (0.09%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

KTRA is trading at a 48% discount.
Price
$0.12
Fair Value
$1.78
Uncertainty
Extreme
1-Star Price
$2.57
5-Star Price
$8.13
Economic Moat
Cjpjd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KTRA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.12
Day Range
$0.120.12
52-Week Range
$0.085.89
Bid/Ask
$0.12 / $0.12
Market Cap
$4.58 Mil
Volume/Avg
835,088 / 15.8 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
2

Valuation

Metric
KTRA
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
KTRA

Financial Strength

Metric
KTRA
Quick Ratio
0.57
Current Ratio
0.63
Interest Coverage
Quick Ratio
KTRA

Profitability

Metric
KTRA
Return on Assets (Normalized)
−202.58%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−547.90%
Return on Assets
KTRA
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYpzkvdnsBkqrm$558.5 Bil
VRTX
Vertex Pharmaceuticals IncPwlmzszLkvjw$103.4 Bil
REGN
Regeneron Pharmaceuticals IncSdtxqnzHtskpm$102.8 Bil
MRNA
Moderna IncDtrshnthkRtb$41.0 Bil
BNTX
BioNTech SE ADRLrkyxnlzJwwwr$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncYgxrvtjkmRmyfryw$19.7 Bil
BMRN
Biomarin Pharmaceutical IncRzvcbdxnWcznvk$17.4 Bil
RPRX
Royalty Pharma PLC Class AGwydpvvnwSbfqtyd$13.0 Bil
INCY
Incyte CorpJmyktvqgGpzsrpv$12.4 Bil
UTHR
United Therapeutics CorpMpjyvtvfWdnx$11.2 Bil

Sponsor Center